思瑞康与思利舒治疗首发精神分裂症的对照研究  

Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia

作　　者：王学文[1] 李宝珠[1] 

机构地区：[1]天津市安定医院,300222

出　　处：《四川精神卫生》2010年第3期153-155,共3页Sichuan Mental Health

摘　　要：目的比较思瑞康和思利舒治疗首发精神分裂症的疗效及安全性。方法将76例符合DSM-Ⅳ诊断标准的首发精神分裂症患者随机分为两组,分别给予思瑞康与思利舒治疗12周。采用阳性症状与阴性症状量表(PANSS)评定疗效,不良反应症状量表(TESS)评定不良反应。结果两组治疗12周后的疗效相当(P>0.05);思瑞康组和思利舒组的显效率差异无显著性(P>0.05);思瑞康组的不良反应发生率低于思利舒组,但差异无显著性(P>0.05);思利舒组锥体外系不良反应和内分泌改变的发生率均明显高于思瑞康组(P<0.05),但两药引起的不良反应一般为轻度或中度,患者耐受性较好。结论思瑞康和思利舒治疗精神分裂症的疗效相当。Objective To compare the efficacy and safety of seroquel and risperidone in the treatment of schizophrenia.Methods 76 patients with schizophrenia by DSM-Ⅳ were randomly divided into two groups treated with seroquel and risperidone for 12 weeks.The positive and negative syndrome scale（PANSS）and treatment emergent symptoms scale（TESS）were used to evaluate efficacy and adverse effects respectively before and at the end of 4,8,12 weeks of treatment.Results The therapeutic efficacy in seroquel group was similar to that in rispeidone group（P0.05）;There was no significant difference between the two groups（P0.05）.Incidence of adverse effects was lower in seroguer group,but there was not the significant difference（P0.05）.The rates of extrapyramidal symptoms and endocrine change were significantly higher in risperidone group than the seroquel group（P0.05）.Weight gain was significantly higher in risperidone group than those in seroquel group（P0.05）.But these side effects were not serious,and patients often had good tolerability for them.Conclusion The results suggest that seroquel is as effective as risperidone for the treatment of schizophrenia,but the 2 agents have different side effects.

关 键 词：思瑞康 思利舒 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]